Ma Hong, M.D., Ph.D.

Department:Cardiology

Medical School:Fudan University, China

Academic Rank:Associate Chief Physician


Appointment

Clinical / Research Interests

Dr. Ma mainly focuses on the clinical management of heart failure and its underlying molecular mechanisms:

1. Diagnosis and treatment of atherosclerotic cardiovascular disease

2. Cardiac arrhythmias and therapy

3. Heart failure management, including pharmacological and device-based therapy

4. Cardiac regeneration, metabolic reprogramming


Professional Highlights

Natural Science Award of Zhejiang Province, First Prize (Second place), 2023

Cardiovascular Research Award of Young Doctors in Zhejiang Province, 2020

Award for Early Career Investigator, International Society for Heart Research, 2019

Award for Big Data Workshop of Translational Omics Research, Purdue University/NIH, 2017

Zhejiang Scientific and Technological Progress Award, First Prize (Third place), 2013



Professional Appointments

Fellow, American College of Cardiology, 2022

Member, Bioactive Small Molecule Professional Committee of the Chinese Pathophysiology Society, 2022

Youth Committee Member, Cardiovascular Branch of Zhejiang Medical Association, 2021

Executive Director, Zhejiang University Young Professor Association, 2019

Member, Council on Basic Cardiovascular Science, American Heart Association, 2018

Member, International Society for Heart Research (ISHR), 2018

Member, Zhejiang Medical Association (Cardiovascular Tissue Repair and Regeneration), 2018


Education Experience

Ph.D., Fudan University, Zhongshan Hospital, 2007-2010


Research Summary

Dr. Ma mainly focuses on heart failure and its underlying molecular mechanisms: 1) Cardiac metabolic reprogramming, regulation, and roles in heart failure; 2) Direct reprogramming to mend a broken heart; 3) Translational research using multi-disciplinary means. He was awarded as Outstanding Youth Science Foundation, Distinguished Young Scholar of Zhejiang Province, Young Committee Member of Zhejiang Society of Cardiology. He has published over 60 articles in Nature, Circulation, Cardiovascular Research (Editor's Choice), Hypertension (High Impact Paper) etc.

Publications

Hong Ma, Shuo Yu, Xiaojing Liu, Yingao Zhang, Thomas Fakadej, Ziqing Liu, Chaoying Yin, Weining Shen, Jason W. Locasale, Joan M. Taylor, Li Qian*, Jiandong Liu*. Lin28a Regulates Pathological Cardiac Hypertrophic Growth through Pck2-mediated Enhancement of Anabolic Synthesis. Circulation. 2019 Apr 2,139(14):1725-1740.

Ziqing Liu#, Li Wang#, Joshua D. Welch#, Hong Ma, Yang Zhou, Haley Ruth Vaseghi, Shuo Yu, Joseph Blake Wall, Sahar Alimohamadi, Michael Zheng, Chaoying Yin, Weining Shen, Jan F Prins, Jiandong Liu*, Li Qian*. Single-cell transcriptomics reconstructs fate conversion from fibroblast to cardiomyocyte. Nature. 2017 Nov 2; 551(7678):100-104.

Hong Ma, Li Wang, Chaoying Yin, Jiandong Liu, and Li Qian. In vivo cardiac reprogramming using an optimal single polycistronic construct. Cardiovasc Res. 2015 Nov 1;108(2):217-9. Editor's Choice


Current Program

Role of Serine Metabolic Enzyme PSAT1 on Cardiac Hypertrophy via RNA Methylation (Principle Investigator). Funding Source: National Natural Science Foundation of China.

Glutamate Metabolism in Heart Failure (Principle Investigator). Funding Source: National Natural Science Foundation of China.

Role of RNA binding Protein PTBP1 in Cardiac Hypertrophy (Principle Investigator). Funding Source: National Natural Science Foundation of China.

Role of PTBP1 in Heart Failure after Myocardial Infarction (Principle Investigator). Funding Source: Natural Science Foundation of Zhejiang Province.


Find People

Search by Family Name

Find A Department

Search by Departments